

**AYURVEDIC MANAGEMENT OF YAKRIT VAISHAMYA W.S.R. TO CIRRHOSIS OF LIVER: A CASE STUDY****Dr. Aparna Singh<sup>\*1</sup>, Dr. Piyush Gupta<sup>2</sup>, Dr. Mohit Bagwari<sup>3</sup>, Dr. Kamal Kishor Joshi<sup>4</sup>**<sup>1</sup>P.G. Scholar, <sup>2</sup>Professor, <sup>3</sup>Assistant Professor, <sup>4</sup>P.G. Scholar,  
Department of Panchkarma, Patanjali Bhartiya Ayurvedigyan Evam Anusandhan Sansthan, Haridwar, Uttarakhand, India.**\*Corresponding Author: Dr. Aparna Singh**

P.G. Scholar, Department of Panchkarma, Patanjali Bhartiya Ayurvedigyan Evam Anusandhan Sansthan, Haridwar, Uttarakhand, India.

DOI: <https://doi.org/10.5281/zenodo.20526137>**How to cite this Article:** Dr. Aparna Singh<sup>1</sup>, Dr. Piyush Gupta<sup>2</sup>, Dr. Mohit Bagwari<sup>3</sup>, Dr. Kamal Kishor Joshi<sup>4</sup> (2026). Ayurvedic Management Of Yakrit Vaishamyia W.S.R. To Cirrhosis Of Liver: A Case Study. World Journal of Pharmaceutical and Medical Research, 12(6), 449-458.

This work is licensed under Creative Commons Attribution 4.0 International license.



Article Received on 05/05/2026

Article Revised on 25/05/2026

Article Published on 03/06/2026

**ABSTRACT**

In the modern era, alcoholism has become a standard in society. Hence, its aftereffects are causing severe health issues in society. Most commonly, people are suffering from liver disorders. Damage to the liver leads to repair of liver tissue and subsequent formation of scar tissue. The scarring is most often caused by long-term exposure to toxins such as alcohol or viral infections. It tends to progress slowly and often does not cause symptoms in its early stages. However, as the function of the liver gradually becomes worse, serious problems can develop. In *Ayurveda*, *Yakrit* is considered as an important *Anga* right from the *vedic* period. *Ayurvedic* classical references are available regarding the enlargement of *Yakrita*. The disease *Yakritdalyudara* has been included in eight types of *Udara roga* in *Ayurvedic* classics. In this article, an effort is made to understand the etiopathogenesis, sign & symptoms of *Yakritdalyudara* & its management mentioned in classical *Ayurvedic* texts along with its modern counterpart. There is no need to say that till date, no definite therapy is available in western system of medicine for the management of terminal diseases like cirrhosis of liver. This is the study of 46-year-old male patient who came to Patanjali Wellness Centre with the major complaints of constipation & skin problem from last 6 months with a history of Diabetes mellitus since 2021 for which *Ayurveda* therapy seem to be very specific for pacifying the vitiated *doshas* ultimately fulfilling the targets of the *Aushadh dravyas*. Also, the diet, lifestyle changes along with *Yogic* exercises, *pathya* plan was strictly advised for 3 months to the patient which showed tremendous results.

**INTRODUCTION**

Liver cirrhosis is a condition which builds up by the process of necrosis and regeneration of hepatocytes ultimately resulting in fibrosis and capillarization of hepatic sinusoid. Decreased hepatic parenchyma, disturbance of blood flow due to fibrosis and abnormal reconstruction, and portosystemic shunt cause portal hypertension, ascites, hepatic encephalopathy, pulmonary, renal and cardiac disturbance, and hyponatremia. Cirrhosis is terminal image of chronic liver disease. During progression from the compensation period to the decompensation period, various complications occur and the life prognosis is significantly reduced. In recent years, medical treatment for liver cirrhosis has made marked progress that can be said to be a paradigm shift. Ascites is a very common manifestation of decompensated cirrhosis and represents

a pathological accumulation of fluid within the peritoneal cavity.<sup>[1]</sup> Cirrhosis is defined histologically as a diffuse hepatic process characterized by fibrosis and the conversion of normal liver architecture into structurally abnormal nodules.<sup>[2]</sup> Most patients, with chronic hepatitis B are asymptomatic and develop complications such as cirrhosis and hepatocellular carcinoma only after many years. Cirrhosis develops in 15-20%, of patients with chronic HBV over 5-20 years. This proportion is higher in those who are e antigen-positive.<sup>[3]</sup>

**Causes of Cirrhosis<sup>[4]</sup>**

Hepatitis B Hepatitis C Autoimmune hepatitis Nonalcoholic steatohepatitis Chronic viral hepatitis Inherited metabolic liver disease	Hemochromatosis Wilson's disease Antitrypsin deficiency
--	---

Liver cirrhosis can occur at any age, has significant morbidity and is an important cause of premature death. It may also occur in prolonged biliary damage or obstruction, as is found in primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and post-surgical biliary structures. Persistent blockage of venous return from the liver, such as is found in sinusoidal obstruction syndrome (SOS veno-occlusive disease) and Budd-Chiari Syndrome, can also result in cirrhosis. Cirrhosis can be classified histologically into:

- **Micronodular cirrhosis**- characterised by small nodules about 1 mm in diameter and typically seen in alcoholic cirrhosis.
- **Macronodular cirrhosis**- characterised by larger nodules of various sizes. Areas of previous collapse of the liver architecture are evidenced by large fibrous scar.<sup>[5]</sup>

Liver diseases are rapidly increasing worldwide, with liver cirrhosis creating a major health and economic

burden. In India, high rates of hepatitis B&C, fatty liver disease, rising alcohol consumption, and increasing non-alcoholic liver disease cases, even in children, contribute significantly to this problem. The global economic impact of liver cirrhosis is estimated to surpass 100 billion USD each year, factoring in both direct healthcare expenses and losses in productivity. Hepatic cirrhosis greatly affects quality of life, productivity, and healthcare expenses.<sup>[6]</sup> Alcohol consumption, viral hepatitis B & C, metabolic syndrome related to obesity are the most common causes of cirrhosis. Ascites is the most common presentation. 50% of compensated cirrhosis develops ascites in 10 years of time. Ascites treatment requires hospitalization, can lead to life threatening complications and need liver transplantation.<sup>[7]</sup> The determination of fibrosis is done on the basis of Fibro scan for liver stiffness, and various other blood investigations.

Various stages of liver diseases:<sup>[8]</sup>

Cause	Effect	Symptom
Inflammation	Liver enlarged or inflamed	No symptom
Fibrosis	Liver scar	No symptom
Cirrhosis	Severe scar	Symptom appears, liver fails, Ascites
End stage liver	Function deteriorates	Hepatic encephalopathy
Cancer of liver (HCC)	Multiplication of unhealthy cells	Liver failure

The description of liver is found in various *Samhitas* such as, *Sushruta Samhita*, *Charaka Samhita* and *Ashtanga Hridaya*. In *Vedas*, Liver is named as “*Yakna*” or “*Takima*”. Other synonyms are *Kalakhanda*, *Jyotisthana*, *Yakritkhanda*, *Yakritpinda*, *Raktadhara* and *Raktashaya* are found in the ancient literature of liver. *Acharya Sushruta* explains that foetal nutrition usually depends *madhura ahara rasa*, categorized under various maternal factors and *Vayu* present in *Jyotisthana*, which is further responsible for cell division. The *ahara rasa* is first received by *Jyotisthana*/liver, which is responsible for nourishment of whole body. Therefore, *Jyotisthana* is interpret with “*Yakrit*” or “*Liver*”. *Acharya Vagbhatta* has used the word *Yakritkhanda* with regards to the description of diseases which is indication for the lobes (*khanda*) of liver. As said by *Acharya Vagbhatta*, the main function of *Yakrit* is to change *Rasa Dhatu* to *Rakta Dhatu*, i.e. *Ranjana* of *Rasa Dhatu* which takes place in liver itself. *Yakrit* is developed or generated from *Matrijibhava*.<sup>[9]</sup> In *Ayurveda*, the diseases of anatomical entities (*dhatu*) manifested through either *vrudhi* (increase of specific quantity) or *kshaya* (decrease of

specific quantity) like *Rasa vrudhi*, *Rasa kshaya*, *Rakta vrudhi*, *Rakta kshaya*, *Mamsa vrudhi*, *Mamsa kshaya* etc. Similar way *Yakrit* is manifested through *Yakrit vrudhi* (Hepatomegaly) and *Yakrit kshaya* (Cirrhosis). *Acharya Sushruta* gave the specific name to the *Yakrit vrudhi* for the first time as *Yakritdalyudara* whereas, *Yakrit kshaya* is narrated in *Bhaishajya Ratnavali*. The hepatology of modern medical science is a lot developed and various other classification of liver diseases are listed in modern science whereas, *Ayurveda* is limited to *Yakritdalyudara roga* and *Yakrit Kshaya*. Although complications of *Yakritdalyudara* and *Yakrit Kshaya* are *Kamala*, *Kumbha Kamala*, *Halimaka*, *Panaki*, *Alasaka* etc are described separately under the chapter of *Pandu Roga* in *Ayurveda*. Thus, the gap in the *Ayurveda* classification of liver diseases can be elaborated in light of modern medicine through consensus studies with sufficient justification. According to *Acharya Charaka* in *Chikitsa Sthana*, all *Udara Rogas* (morbid abdominal diseases) ultimately progress to the stage of *Ascites/ Jaloudara*. In this context, the *Ayurvedic* management protocol mainly aims at improving *Koshtagni* (abdominal digestive fire/

metabolism) and helping to stimulate the physiological functions of the liver.

#### SAMPRAPTI GHATAKA OF YAKRIT VIKARA IN AYURVEDA<sup>[10]</sup>

- **Dosha-** *Samaan Vata* (subtype of *Vata*), *Pachaka Pitta* (subtype of *Pitta*).
- **Dushya-** *Pachakagni* (digestive fire), *Rasa* (Plasma)-*Rasa dhatu* (Nutrient fluid).
- **Adhishthana (Location of Disease)-** *Amashaya* (Stomach), *Grahani* (Small Intestine).

- **Srotas (Annavaha)-** The disease involves *Amashaya*, *Grahani*, and *Pakvashaya* (Large Intestine). *Annavaha Srotas* appears to be the main concern, but *Rasavaha Srotas* (Plasma channels), in which *Ama* (Toxin) is first produced due to impaired *Agni* (Digestive fire), may also get involved.
- **Dushtiprakar (Type of Disease)-** *Sanga* (Obstruction).
- **Agni (Digestive Fire)-** *Mandagni* (weak digestion).
- **Rogmarga (Pathway)-** *Abhyantra rogmarga* (Internal Pathways of Disease).

#### SAMPRAPTI CHAKRA OF YAKRIT VIKARA IN AYURVEDA

Excessive consumption of *Nidana- Kshara* (alkaline substances), *Amla* (sour foods), and *Lavana* (salty foods), along with intake of *Virudha Ahara* (incompatible food combinations), *Vidagdha Anna* (putrefied/stale food), and *Asatmya Ahara* (unsuitable or unwholesome diet). Consumption of *Nishpava* (flatulent legumes), *Masha* (black gram), and *Pinyaka* (oil cake), along with habits such as *Ativyayama* (excessive physical exertion), *Atimathun* (excessive sexual activity), *Diwaswapna* (daytime sleep), *Kama* (excessive desire), *Chinta* (anxiety), *Bhaya* (fear), *Krodha* (anger), and *Vegadharana* (suppression of natural urges).



Development of *Mandagni* (reduced or weakened digestive/metabolic fire).



Formation of *Apakva Anna Rasa* (improperly metabolized food essence) along with *Mala Sanchaya* (accumulation of toxic waste products).



*Dosha Dushti* involving mainly *Pachaka Pitta*, *Kledaka Kapha*, and *Trimala* [*Mala* (stool), *Mutra* (urine), and *Sweda* (sweat)], along with disturbance of *Samana Vata* (digestive *vata*), *Prana Vata* (vital *vata*), and *Apana Vata* (excretory *vata*).



*Sroto Dushti* (vitiation/of body channels), mainly affecting the *Swedavaha* and *Ambuvaha Srotas* (sweat and fluid-carrying channels).



Ultimately leading to *Yakrit Vikara*.

#### CASE REPORT

A 46-year-old male patient, visited Patanjali Wellness Centre, Haridwar, Uttarakhand, India, on 08/12/2023

with the complaints of weakness & constipation from past 6 months along with 5 kg weight loss over the last 1 year and generalized itching all over the body with

diagnosed case of Cirrhosis of Liver along with Ascites. Patient also had a Post-Covid History of Diabetes Mellitus since 2021.

**3) Weight:** 64 kg  
**4) Height:** 165 cm.

❖ **Vitals on the initial visit**

1) **Blood Pressure:** 139/82 mmHg  
2) **Pulse Rate:** 69 bpm

❖ **Asthavidha Pariksha on the first day visit of the patient**

S.NO.	PARAMETERS	FINDINGS
1.	<i>Nadi</i> (Pulse)	<i>Vata-Pittaja</i>
2.	<i>Mala</i> (Stool)	<i>Abadh</i> (loose)
3.	<i>Mutra</i> (Urine)	<i>Ishatpeeta</i> (normal)
4.	<i>Jihva</i> (Tongue)	<i>Saama</i> (coated)
5.	<i>Shabda</i> (Speech)	<i>Spashta</i> (clear)
6.	<i>Sparsha</i> (Touch/Palpation)	<i>Anushna sheeta</i> (normal temp.)
7.	<i>Drika</i> (Eyesight)	<i>Avikrit</i> (normal)
8.	<i>Akriti</i> (Body shape)	<i>Madhyam</i> (normal)

**1. Complaints with Duration are mentioned below**

S.No.	Symptoms	Duration
1.	Constipation	x 6 months
2.	Headache	x 4 months
3.	Distention of Abdomen	x 4 months
4.	Itching over skin	x 2 months
5.	Weakness	x 2 months

**2. General Examination**

Icterus	2+
Pallor	1+
Oedema	Absent
Blood pressure	132/84 mmHg
Built	Moderate
Weight	55kg

**3. Addiction History**

Tobacco chewing	Approximately 3 packs daily for the last 21 years.
Alcohol consumption	Occasional intake for the last 21 years
Tea consumption	3-4 times daily

**4. Past History**

DM-2 since 2021, Hepatitis B positive since 2008- diagnosed accidentally during routine checkup.

**5. Treatment History**

Metformin 500mg twice daily, discontinued for the past 3 months.

**INTERVENTION**

**I. Ahara Krama:** The dietary guidelines provided by Patanjali Wellness Centre included the following

➤ **“Do’s & Dont’s” -**

- Smile with loving & joyous heart thank God for happy, holy & healthy life. Drink two glass of plane copper/silver/gold/charged water.
- Eat small portions of solid food & chew each bite thoroughly around 32 times to support better digestion & nutrient absorption.
- Avoid tea, coffee, sugar, spicy & fried foods, trans fats, junk/fast foods, carbonated drinks, processed or

refined foods, artificial additives, alcohol, tobacco & smoking.

- Drink about 250ml alkaline water 3-4 times a day.
- Consume early morning at 5:30 AM: lemon with lukewarm plain water/fenugreek, wheat or barley water along with 2 tsp of honey, or herbal decoction.
- Consume a mixed juice of fresh *amla*, aloevera, *giloy*, carrot, beetroot, spinach & wheatgrass.
- Give preference to alkaline food such as: Natural Yellow, Purple, Green, Red, Orange, Blue colorful fresh fruits & vegetable as Carrot, Tomato, Spinach etc. Sprouted cereals, pulses, seeds, hand pounded brown rice, whey, butter milk, jaggery, honey.
- Do not consume water while taking food, drink hot water sip by sip while taking food only to prevent gas formation (if any).

➤ **Ayurvedic and Disciplined Intelligent Person's diet (DIP)**

TIME	MEAL	ITEMS INCLUDED
5:00 AM	Early morning	2 glasses of plane water
5:30 AM	Early morning	Herbal decoction
5:40 AM-7:00 AM	Early morning	Soaked almonds (7) + Raisins (7)
11:00 AM	Pre-lunch	Boiled Bottle gourd
12:00 PM	Lunch	<i>Jau Daliya</i> , Soup + Salad + Butter milk
12:45 PM	Post-lunch	<i>Punarnava</i> juice
3:00 PM	Seasonal Fruits	Pomegranate, Papaya, Mulberry, Mango, Water Melon/Musk Melon- One type of fruit at a time.
6:00 PM	Pre-dinner	Goat milk + <i>Trikatu churna</i>
7:00 PM-8:00 PM	Dinner	Boiled <i>Torai</i>
8:45 PM	Post-dinner	Goat milk + <i>Trikatu churna</i>

**II. Fasting:** Once every week.

**III. Additional Lifestyle Guidelines (Special Instructions)**

- Offer a moment of gratitude to the Almighty before eating or drinking anything.
- Practice Vajrasana after every meal.
- Take a gentle 10-minute walk following each meal.

**IV. Dincharya:** Yoga (Pranayama), Meditation for relaxation, Barefoot brisk walking.

**TREATMENT PLAN**

The treatment was planned according to the *Doshas* and *Dushyas* involved in the disease in order to break the *Samprapti*. *Pitta*-pacifying and *Yakrituttejaka dravyas* were administered to the patient as mentioned below

S.NO.	AUSHADH DRAVYA	DOSE & ANUPANA
1.	<i>Sarvakalpa Kwath</i> + <i>Vrikkdoshahara Kwath</i>	100ml X BD E/S
2.	Tablet Livogrit Vital Tablet <i>Madhunashni</i> Extra Powder	2 X TID B/F with lukewarm water
3.	Tablet Livamrit Advance Tablet <i>Madhugrit</i> Tablet <i>Punarnavadi Mandoor</i>	2 X TID A/F with lukewarm water.

**Suggested Yoga**

S.NO.	YOGA NAME	DURATION
1.	(Pranayama) <i>Anulom-Vilom</i>	45 minutes
2.	(Asana) <i>Shavasana</i>	10 minutes
3.	(Asana) <i>Vakrasana</i>	2 minutes
4.	(Asana) <i>Ardhamatasyendrasana</i>	2 minutes
5.	(Asana) <i>Gomukhasana</i>	2 minutes
6.	(Asana) <i>Mandookasana</i>	5 minutes
7.	(Asana) <i>Yogmudrasana</i>	2 minutes

**MEDICATIONS ADMINISTERED DURING TREATMENT**

S.NO.	AUSHADH DRAVYAS	GHATAKA DRAVYA	DOSAGE WITH ANUPANA
1.	<i>Sarvakalpa Kwath</i>	<i>Punarnava, Bhumi Amla, Makoy</i>	Take & boil 2 tsp of <i>Kwath</i> drug into 400ml of water. When it reduces to 100 ml, then strain it & take empty stomach in the morning & evening, 1 hour before meal, for 30 days.
2.	<i>Vrikkdoshahar Kwath</i>	<i>Dhak, Pitpapra, Punarnava, Pashanbhed, Varun, Kulthi, Apamarg, Kasni, Pippal, Neem, Makoy, Gokhru, Dhamasa, Kush, Kash, Dhan, Sarkanda, Ikshu, Oontkatara, Giloy, Ami, Amaltas, Bala, Satavari, Vidari, Choti Kateri, Badi Kateri, Jav, Kutaki</i>	Take & boil 2 tsp of <i>Kwath</i> drug into 400ml of water. When it reduces to 100 ml, then strain it & take empty stomach in the morning & evening, 1 hour before meal, for 30 days.
3.	Livogrit Vital	<i>Punarnava, Bhumi Amla, Makoy, Rose hip, Spinach, Corn. Excipients: Gum acacia, Resin, Talcum, MCC,</i>	Take 2 tab. Of medicine, 30 minutes after breakfast/lunch/dinner with

		Croscarmellose sodium.	lukewarm water for 30 days.
4.	<i>Madhunashini Vati Extra Powder</i>	<i>Giloy, Karela, Bel patra, Gudmar, Harad chhoti, Gokhru, Vat jata, Haldi, Methi, Kuda chhal, Neem patra, Ashwagandha, Baheda, Kalmegha, Kachur, Neem, Amla, Shilajeet shuddh. Fine powders of: Jamun, Kali jeeri, Chirayata, Kutki, Babul, Kuchla Shuddh, Atish, Praval Pishiti, Vang Bhasma, Lauh Bhasma. Excipients: Gum acacia, Aerosil, Talcum.</i>	Take 2 tab. Of medicine, 30 minutes after breakfast/lunch/dinner with lukewarm water for 30 days.
5.	<i>Livamrit Advance</i>	<i>Bhumi Amla, Makoy, Daruhaldi, Kasani, Dronpushpi, Punarnava, Atibala, Erand, Giloy, Kalmegh, Sonapatha, Sharpunkha. Powder of: Kutki. Excipients of: Gum acacia, Talcum, MCC, HPMC, Aerosil.</i>	Take 2 tab. Of medicine, 30 minutes after breakfast/lunch/dinner with lukewarm water for 30 days.
6.	<i>Madhugrit</i>	<i>Chandraprabha Vati, Shuddh Shilajit, Giloy, Indrayana, Karela, Chirayata, Shatavar, Ashwagandha. Excipients: Gum acacia, Talcum, MCC, Croscarmellose sodium.</i>	Take 2 tab. Of medicine, 30 minutes after breakfast/lunch/dinner with lukewarm water for 30 days.
7.	<i>Punarnavadi mandoor</i>	<i>Punarnava, Nishoth, Sonth, Pippal, Mirch, Vayavidanga, Devdaru, Chitrak, Pushkarmool, Haldi, Daruhaldi, Danti, Harad, Baheda, Amla, Chavya, Pipparmool, Nagarmotha, Mandoor Bhasma. Processed with: Gaumutra Q.S.</i>	Take 2 tab. Of medicine, 30 minutes after breakfast/lunch/dinner with lukewarm water for 30 days.

#### ADMINISTERED PANCHKARMA THERAPIES

(1) **PARISHEKA** with *Dashmoola Kwath + Gokshura Kwath*

(2) **LIVER BASTI** with *Sahacharadi Taila*

(3) **NIRUHA BASTI (KSHEER)** with *Gaudugdha (200ml) + Gaughrita (20ml) + Castor Oil (40ml) + Madhu (20ml) + Saindhav Lavana (3gm).*

- All three *Panchkarma* therapies were administered for a duration of seven days.

#### DIET MANAGEMENT

- Fluid restriction was up to 1.5 L per day. It included 500 ml milk per day, boiled rice water, green gram soup measures 100 ml twice a day and medicinal decoctions and juices which was approximately 20-100 ml twice a day.
- Complete salt restricted diet was administered.

#### PATHYA-APATHYA

<b>Pathya Ahara</b>	<b>Pathya Vihara</b>
<ul style="list-style-type: none"> <li><i>Madhuka</i> (honey with lukewarm water).</li> <li>Fruits/Salads preferably with breakfast, Milk (double toned) 200 ml once or twice in a day.</li> <li><i>Mugda Yusha</i> (<i>Mugda yusha, Yava, Patola, Amlaki</i>).</li> </ul>	<ul style="list-style-type: none"> <li>Barefoot brisk walking.</li> <li><i>Surya Namaskar</i></li> <li><i>Bhramari</i></li> <li><i>Udgit</i></li> <li><i>Pranayama</i></li> <li><i>Bhastrika</i></li> </ul>
<b>Apathya Ahara</b>	<b>Apathya Vihara</b>
<ul style="list-style-type: none"> <li>Coffee, tea, smoking, tobacco, chewing <i>pan masala</i>, alcohol, <i>Vidahi ahara</i>.</li> </ul>	<ul style="list-style-type: none"> <li><i>Ati nidra</i> (excessive sleep).</li> <li><i>Ati bhojana</i> (over-eating/untimely eating).</li> </ul>

## BEFORE TREATMENT

Scanned by CamScanner

ARTH DIAGNOSTICS  
NABL & NABH  
NABL 401100240

Name : Mr. MANISH TAK  
Age/Gender : 46 YRS/MALE  
Centre : Walk-in  
Ref. By : Dr. L. S. CHOUHAN M.D.(Medicine)

Lab No. : 012309100240  
Sample Received : 10/Sep/2023 12:53PM  
Result Reported : 10/Sep/2023 01:59PM  
Reg. No. : 840777

**HAEMATOLOGY**

Test Name	Result	Unit	Normal Value	Method
<b>RBC Parameter</b>				
HAEMOGLOBIN	17.20	g/dL	14.0-17.5	
RBC Count	5.50	M/mm <sup>3</sup>	4.5-5.5	
PCV	49.50	%	40.0-50.0	
MCV	90.70	fL	80.0-100.0	
MCH	31.50	pg	27.0-32.0	
MCHC	34.70	g/dL	32.0-36.0	
RDW-CV	12.2	%	11.0-14.5	
<b>WBC Parameter</b>				
TLC (Total Leucocyte Count)	6200	/mm <sup>3</sup>	4000-11000	
<b>Differential Leucocyte Count</b>				
Neutrophil	55	%	40-75%	
Lymphocyte	35	%	20-40%	
Eosinophil	6	%	1-6%	
Monocytes	4	%	2-10%	
<b>Platelet Parameter</b>				
Platelet Count	1.70	Lacs/mm <sup>3</sup>	(1.50-4.50)	
Mean Platelet Volume	10.60	fL	7.5-11.0	

\*RBCs are normocytic normochromic.  
\*WBCs are normal.  
\*Platelets are adequate and are normal in morphology.  
\*No immature cells or haemoparasite is seen.  
**IMPRESSION: NORMAL PBF STUDY.**

Dr. Ashish Pandey  
M.D. (Pathology)  
NABH 401100240

AC, Apex Chamber, Bahadur Lok Kala Mandal, Opp. Canara Bank, Madhuban, Patna-801115  
Tel: 7073308880, 7073818880 | 0723929900 | www.arthdiagnostics.com

Scanned by CamScanner

ARTH DIAGNOSTICS  
NABL & NABH  
NABL 401100240

Name : Mr. MANISH TAK  
Age/Gender : 46 YRS/MALE  
Centre : Walk-in  
Ref. By : Dr. L. S. CHOUHAN M.D.(Medicine)

Lab No. : 012309100240  
Sample Received : 10/Sep/2023 12:53PM  
Result Reported : 10/Sep/2023 02:47PM  
Reg. No. : 840777

**BIOCHEMISTRY**

Test Name	Result	Unit	Normal Value	Method
SGPT (ALT), Serum	62.80	U/L	9.00-49.00	IFCC without pyridoxal phosphate
SGOT (AST), Serum	57.40	U/L	9.00-49.00	IFCC without pyridoxal phosphate
<b>BILIRUBIN-TD/IND</b>				
Bilirubin Total	0.60	mg/dL	0.1-1.10	
Bilirubin, Direct	0.300	mg/dL	0.0-0.40	Diazo
Bilirubin, Indirect	0.300	mg/dL		



**AFTER TREATMENT**

**MAHARANA BHUPAL GOVT. HOSPITAL, UDAIPUR**  
 MUKHYAMANTRI NISHIKL NIROGI RAJASTHAN YOJANA

Patient Name: MR. MANISH  
 Age/Gender: 46 Y / M / O / M  
 Ref Doctor: Dr. S.P.P.  
 Inpatient/Emergency: RNT HOSPITAL  
 State: Rajasthan

Lab No: 1  
 CH No: 04/Apr/2024 12:00  
 Remarks No: 10937384  
 Address: BAYANA UDA

Test Name	Result	Unit	Bio. Ref. Range	Method
<b>BILIRUBIN IN SERUM BLOOD</b>	19.70	mg/dl	1.0-1.5	Biochemistry
Serum Urea	18.9	mg/dl	16.0-48.0	Urea and Urea
Serum Creatinine	1.1	mg/dl	0.7-1.2	Colorimetric
Bilirubin, Total	0.579	mg/dl	0 - 1.2	Colorimetric
Bilirubin, Direct	0.260	mg/dl	0.1-0.2	Colorimetric
Bilirubin, Indirect	0.30	mg/dl	0.1-0.2	Colorimetric
SGOT	84	U/L	10 - 50	Colorimetric
SGPT	66	U/L	10 - 50	Colorimetric
Alkaline Phosphatase	99	U/L	40 - 129	Colorimetric
TOTAL PROTEIN	6.9	g/dl	6.6-8.7	Colorimetric
Albumin	4.88	g/dl	3.0 - 4.1	Colorimetric
A/G RATIO	1.39		1.0 - 2.0	Calculated
Serum Albumin	4.0	g/dl	3.5-5.0	Colorimetric
SERUM CALCIUM	9.2	mg/dl	8.6-10.0	Colorimetric
UREA ACID	16.6	mg/dl	2.4-7.0	Colorimetric
SERUM CHOLESTEROL	167.0	mg/dl	80 - 200	Colorimetric
Triglycerides	187.9	mg/dl	0 - 150	Colorimetric
HDL Cholesterol	40.7	mg/dl	35-55	Colorimetric
LDL Cholesterol	114.9	mg/dl	0 - 100	Colorimetric
VLDL	53.4	mg/dl	15 - 30	Colorimetric

**DYSLIPIDEMIA. ADV. FASTING T.G.**

Dr. Manish Sharma  
 MBBS, MD, DM (Gastroenterology)  
 RNT MEDICAL COLLEGE, UDAIPUR  
 BIC-800008


**MAHARANA BHUPAL GOVT. HOSPITAL, UDAIPUR**  
 MUKHYAMANTRI NISHIKL NIROGI RAJASTHAN YOJANA

Patient Name: MR. MANISH  
 Age/Gender: 46 Y / M / O / M  
 Ref Doctor: Dr. S.P.P.  
 Inpatient/Emergency: RNT HOSPITAL  
 State: Rajasthan

Lab No: 1  
 CH No: 04/Apr/2024 13:43  
 Remarks No: 10937384  
 Address: BAYANA UDA

Test Name	Result	Unit	Bio. Ref. Range	Method
URINARY PROTEIN	0.39	mg/dl		Colorimetric
URINE CREATININE	105.00	mg/dl		Colorimetric
URINE ALBUMIN CREATININE RATIO	0.37	mg/g	<30.0	Colorimetric

Dr. Manish Sharma  
 MBBS, MD, DM (Gastroenterology)  
 RNT MEDICAL COLLEGE, UDAIPUR  
 BIC-800008



### COMPARISON OF FIBRO SCAN BEFORE & AFTER TREATMENT

PARAMETER	FINDINGS (VALUES)	NORMAL RANGE
	23/11/2023	
CAP (dB/m)	236	< 238 dB/m (No steatosis)
E (kPa)	12.3	< 6.0 kPa (Normal liver stiffness)
	28/02/2024	
CAP (dB/m)	208	< 238 dB/m (No steatosis)
E (kPa)	8.8	< 6.0 kPa (Normal liver stiffness)

- The Fibro Scan results show changes in CAP (Controlled Attenuation Parameter) & Liver stiffness values (E[kPa]) over the course of treatment, which reflects liver fat content reduced from 236 to 208 by February 2024, suggesting improvement. Liver stiffness (E[kPa]), an indicator of liver fibrosis, decreased from 12.3 to 8.8 indicating regression in liver fibrosis & a positive response to the treatment.

### DISCUSSION

Liver cirrhosis is a progressive disorder marked by fibrosis & impaired liver function. In *Ayurveda*, the condition can be correlated with *Yakrit Vikara* involving *Pitta Dosha*, *Mandagni*, *Ama* formation, & *srotorodha*. The development of fibrosis & ascites can be understood as a consequence of *srotorodha*, impaired *Ranjaka Pitta* function, & disturbance in *Rasa-Rakta Dhatu* metabolism. *Panchkarma* therapies were administered to facilitate *Dosha Shamana* & improve physiological functioning of liver. Strict diet regulation & lifestyle modifications also played a major role in the management. *Niruha Basti* prepared with *Ksheera*, *Ghrita*, *Eranda Taila*, *Madhu*, and *Saindhava lavana* pacify *Vata dosha*, improved bowel evacuation, & enhance digestion & detoxification. In Liver Cirrhosis, there is *Rakta kleda*. The *kleda* state of the *doshas* becomes excessively aggravated within the body. This represents a type of *Medogata Pitta* condition, indicating the predominance of both *Kapha* & *Pitta* in the disease pathology. If oil-based therapies had been administered, the *Snigdha*, *Ushna*, & *Guru* properties of the oil could have further aggravated the *kleda* state. Therefore *Anuvasana Basti* (oil enema therapy) was not used.

Instead *Rukshana Chikitsa* (drying therapy) was incorporated into the treatment protocol.

### CONCLUSION

In conclusion, Liver Cirrhosis is a chronic progressive disorder associated with fibrosis, impaired liver function, portal hypertension, ascites, and multiple systematic complications that significantly affect quality of life. In *Ayurveda*, this condition can be correlated with *Yakrit Vikara* & *Yakrit Kshaya*, where *Mandagni*, *Ama* formation, *Dosha dushti*, and *srotorodha* play a major role in the pathogenesis. The present case study highlights the potential role of *Ayurvedic* management in improving the clinical condition of a patient suffering from cirrhosis of liver with ascites.

The treatment protocol focused on correcting *Agni*, pacifying vitiated *Doshas*, improving liver metabolism, and eliminating accumulated toxins through appropriate *Aushadh Dravyas*, *Panchkarma* therapies, Dietary regulation, and lifestyle modifications. Therapies such as *Parisheka*, Liver *Basti*, and *Niruha Basti*, along with hepatoprotective *Ayurvedic* formulations, showed encouraging outcomes in the patient. Strict adherence to *Pathya Ahara*, fluid restriction, *Yogic* practices, and disciplined lifestyle measures also contributed significantly to the overall improvement.

Objective findings demonstrated improvement in Fibro Scan parameters, with reduction in liver stiffness and CAP values, indicating regression in fibrosis & better hepatic functioning. Clinical symptoms such as abdominal distention, constipation, weakness, and itching were also reduced considerably.

This case study suggests that an integrative *Ayurvedic* approach may help in the effective management of liver cirrhosis and associated complications by improving digestion, metabolism and liver function. However larger clinical studies and long-term follow-up are required to establish the therapeutic efficacy and scientific validation of these *Ayurvedic* interventions in chronic liver diseases.

## REFERENCES

1. Moore CM, Van Thiel DH. Cirrhotic ascites review: Pathophysiology, diagnosis and management. *World J Hepatol.*, 2013; May 27 5 (5): 251-63. Doi:10.4254/wjh. v5.i5.251. PMID: 23717736 PMCID: PMC3664283.
2. Pandey, A.K., Hindi, D. (2023). *Udara roga/Jaloudara nidana evam chikitsa*. In *Udara Chikitsa* (Reprint ed., Chap.2, p.396). central Council for Research in *Ayurvedic* Sciences (CCRAS), Ministry of AYUSH, Government of India.
3. Pandey, A.k. (2023). *Udar roga/Jaloudara nidana evam chikitsa*. In *Kaya Chikitsa* (Reprint ed., Vo. 2, Chap. 2: 386). Central Council of Indian Medicine, New Delhi.
4. Pandey, A.K., Hindi, D. (2023). *Udara roga/Jaloudara nidana evam chikitsa*. In *Udara Chikitsa* (Reprint ed., Chap.2, p.396). central Council for Research in *Ayurvedic* Sciences (CCRAS), Ministry of AYUSH, Government of India.
5. Ralston, S.H., Penman, I. D., STRACHAN, M.W. J., & Hobson, R.P (Eds). 2018; *Davidson's principles and practice of medicine* (23<sup>rd</sup> ed., Chapter 22: Hepatology, p.866). Elsevier.
6. Acharya, R. (2024). Integrating *Panchakarma* in Contemporary clinical practice: Enhancing therapeutic efficacy. *Journal of Research in Ayurvedic Sciences*, 8(3): 99-103.
7. B.R. Tubaki, Saish C. Gawas, Himani Negi, Effect of *Ayurveda* Management on Liver Cirrhosis with Ascites-A Retrospective Cohort Study, *Journal of Ayurveda and Integrative Medicine*, 13(2) 2022; 100508.
8. Panda, Ashok. (2020). *Ayurveda* Management of Liver Diseases (*Yakrit Vikara*).
9. *Vagbhata*. (n.d.). *Astanga Hridayam* (Dr. Brahmanand Tripathi, Ed. & Hindi commentary *Nidana Sthana*, Chapter 12, *Sloka* (23)515). *Chaukhamba Sanskrit Pratishthan*.
10. Manish, A., Sharma, I., Chaudhary, G., Singh, R., Singh, S.P., Singh, M., Sharma, P., & Bhardwaj, R. (2025). Holistic *Ayurvedic* management of *Yakrit vikar*: A case-based study on chronic liver disease. *International Journal of Creative Research Thoughts (IJCRT)*, 13(7), Article IJCRT2507749.